Provided by Tiger Trade Technology Pte. Ltd.

AKESO

108.700
+2.4002.26%
Volume:16.11M
Turnover:1.72B
Market Cap:100.11B
PE:-88.18
High:109.900
Open:102.100
Low:101.000
Close:106.300
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.39
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.233
ROE:-13.59%
ROA:-4.57%
PB:10.10
PE(LYR):-88.18
PS:24.83

Loading ...

HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Tiger Newspress
·
Sep 21

Movement Alert|AKESO Rises 3.65% in Regular Trading, Multiple Brokerages Raise Target Prices Following Strong OS Data from Ivonescimab

Market Focus
·
Sep 21

Akeso Wins China NMPA Phase I Clearance for Egfr/trop2 Bispecific ADC Ak158d1

Reuters
·
Sep 17

RemeGen's RC148 Challenges Akeso's Dominance in Lung Cancer Space, Projected to Hit 3.6B Yuan in Peak Sales

Deep News
·
Sep 17

CICC Raises AKESO Price Target by 8.3% to HK$130, Keeps "Outperform Industry" Rating

Stock News
·
Sep 17

Movement Alert|AKESO Falls 3.04% in Regular Trading, Profit-Taking Follows WCLC Data Catalyst Digestion

Market Focus
·
Sep 16

Jefferies Reaffirms Bullish Stance on AKESO, Sets Price Target at HK$226

Deep News
·
Sep 15

Jefferies Highlights Positive HARMONi-2 Results for AKESO, Reaffirms Buy Rating with HK$226 Target

Stock News
·
Sep 15

Southbound Capital Flow: Net Buying Reaches HK$4.471 Billion, with Heavy Inflows into AI Hardware Stocks and Z.AI (02513) Attracting Over HK$1.2 Billion

Stock News
·
Sep 14

JPMorgan Highlights Strong Overall Survival Data from Akeso's HARMONi-2 Trial, Reaffirms Overweight Rating

Stock News
·
Sep 14

Big Pharma is Pouring Billions into China's Biotechs

Dow Jones
·
Sep 14

Citi Highlights Akeso's HARMONi-2 Overall Survival Edge, Reaffirming Buy Rating on Differentiation

Stock News
·
Sep 14

HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback

Stock News
·
Sep 14

AKESO Shares Climb After WCLC Data Highlights OS Benefit of Lead Drug Versus Keytruda

Deep News
·
Sep 14

Movement Alert|AKESO Rises 3.65% in Regular Trading, Ivonescimab HARMONi-2 OS Data Presented at WCLC

Market Focus
·
Sep 14

Akeso Says Phase III HARMONi-2 Trial Shows Ivonescimab Lifts Overall Survival vs Pembrolizumab in PD-L1-Positive NSCLC

Reuters
·
Sep 13

Movement Alert|AKESO Declines 3.21% in Regular Trading, Trading at HK$90.85

Market Focus
·
Sep 11

Movement Alert|AKESO Falls 3.06% in Regular Trading, Trading at HK$97.9

Market Focus
·
Sep 07

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

Hong Kong Stock Connect Biotech Surges: Dual-Antibody Outperforms Keytruda, Sector Heats Up

Deep News
·
Sep 06